Jorge Cortes, MD
M.D. Anderson Cancer Center
24
17
15
N/A
0
18
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+32 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (20)
Showing 10 of 20 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Patrick Chaftari, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Maro Ohanian, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Ehab Atallah, MD
Medical College of Wisconsin
Shared therapeutic areas:
Worked with same sponsors:
Richard A Larson, MD
University of Chicago
Shared therapeutic areas:
Worked with same sponsors:
Moshe Talpaz, MD
Univ. of Michigan Comprehensive Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
H.Jean Khoury, MD
Emory University
Shared therapeutic areas:
Worked with same sponsors:
Hedy P Smith, MD
Tufts Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Javier Pinilla-Ibarz, MD,PhD
H. Lee Moffitt Cancer Center and Research Institute
Shared therapeutic areas:
Worked with same sponsors:
B. Douglas Smith, MD
Sidney Kimmel Cancer Center at Johns Hopkins
Shared therapeutic areas:
Worked with same sponsors:
David Snyder, M.D.
City of Hope Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (24)
Showing 20 of 24 trials
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
Study of Ibrutinib in Subjects With Acute Myeloid Leukemia
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia
Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)